(4S)-5-(4-chlorophenyl)-N'-(4-chlorophenyl)sulfonyl-N-methoxy-4-phenyl-3,4-dihydropyrazole-2-carboximidamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (4S)-5-(4-chlorophenyl)-N'-(4-chlorophenyl)sulfonyl-N-methoxy-4-phenyl-3,4-dihydropyrazole-2-carboximidamide
• 化学式: C₂₃H₂₀Cl₂N₄O₃S
• 分子量: 503.4
• InChiKey: GWXOJBLPPWKHFZ-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  91.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
  申请人：——

  公开号：US20040248944A1

  公开（公告）日：2004-12-09

  The present invention relates to a group of novel 4,5-dihydro-1H-pyrazo, derivatives which are potent cannabinoid (CB1) receptor antagonists with utility for the treatment of diseases connected with disorders of the cannabinoid system. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification. The invention also relates to methods for the preparation of these compounds, and to pharmaceutical compositions containing one or more of these compounds as an active component. 1

  本发明涉及一组新颖的4,5-二氢-1H-吡唑衍生物，它们是有效的大麻素（CB1）受体拮抗剂，可用于治疗与大麻素系统紊乱相关的疾病。这些化合物具有通式（I），其中符号具有规范中给出的含义。本发明还涉及制备这些化合物的方法，以及含有这些化合物之一或多个作为活性成分的药物组合物。
• NOVEL 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY
  申请人：Solvay Pharmaceuticals B.V.

  公开号：EP1429761A1

  公开（公告）日：2004-06-23
• US7528162B2
  申请人：——

  公开号：US7528162B2

  公开（公告）日：2009-05-05
• [EN] NOVEL 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY<br/>[FR] NOUVEAUX DERIVES 4,5-DIHYDRO-1H-PYRAZOLE PRESENTANT UNE ACTIVITE ANTAGONISTE A CB1
  申请人：SOLVAY PHARM BV

  公开号：WO2003026647A1

  公开（公告）日：2003-04-03

  The present invention relates to a group of novel 4,5-dihydro-1H-pyrazole derivatives which are potent cannabinoid (CB1) receptor antagonists with utility for the treatment of diseases connected with disorders of the cannabinoid system. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification. The invention also relates to methods for the preparation of these compounds, and to pharmaceutical compositions containing one or more of these compounds as an active component.